|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13).
|
9576949 |
1998 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
By analogy with these, we propose that the RAMP-FGFR1 fusion product will contribute to progression of this myeloproliferative disorder by constitutive activation of tyrosine kinase function.
|
9499416 |
1998 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Characterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation.
|
10480903 |
1999 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The 8p12 myeloproliferative disorder. t(8;19)(p12;q13.3): a novel translocation involving the FGFR1 gene.
|
11122115 |
2000 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33).
|
10688839 |
2000 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Further FISH indicated a breakpoint within fibroblast growth factor receptor 1 (FGFR1), the receptor tyrosine kinase that is known to be disrupted in a distinctive myeloproliferative disorder, most commonly by fusion to ZNF198.
|
11739186 |
2001 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL.
|
11746971 |
2001 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Finally, translocations associated with the rare 8p11 myeloproliferative syndrome and other atypical myeloproliferative disorders have permitted the identification of a number of novel fusion proteins involving fibroblast growth factor receptor-1.
|
11640868 |
2001 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
LHGDN |
Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL.
|
11746971 |
2001 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3).
|
12393597 |
2003 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.
|
15448205 |
2004 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
The t(8;13) translocation, found in a rare and aggressive type of stem cell myeloproliferative disorder, leads to the generation of a fusion protein between the N-terminal gene product of fused in myeloproliferative disorders (FIM)/ZNF198 and the fibroblast growth factor receptor 1 (FGFR1) kinase domain.
|
14672707 |
2004 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
FOP-FGFR1 tyrosine kinase, the product of a t(6;8) translocation, induces a fatal myeloproliferative disease in mice.
|
12969958 |
2004 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
ZNF198 is fused with FGFR1 in an atypical myeloproliferative disease that results in constitutive activation of the kinase domain and mislocalization to the cytoplasm.
|
15975576 |
2005 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion.
|
15870860 |
2005 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease.
|
16410451 |
2006 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
The ZNF198/FGFR1 fusion gene in atypical myeloproliferative disease produces a constitutively active cytoplasmic tyrosine kinase, unlike ZNF198 which is normally a nuclear protein.
|
17027752 |
2006 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Combined translocation with ZNF198-FGFR1 gene fusion and deletion of potential tumor suppressors in a myeloproliferative disorder.
|
17321332 |
2007 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We describe a case of coexisting BCR-ABL negative myeloproliferative disorder and precursor T-cell lymphoblastic lymphoma associated with t(8;13) involving FGFR1 at 8p11 in a 14-year-old boy who presented with generalized lymphadenopathy and an abdominal mass.
|
16777224 |
2007 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
The 8p11 myeloproliferative syndrome (EMS) is an aggressive, atypical stem cell myeloproliferative disorder associated with chromosome translocations that disrupt and constitutively activate FGFR1 by fusion to diverse partner genes.
|
17698633 |
2007 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: report of a new case and review of the literature.
|
18096225 |
2008 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Rearrangements of the genes encoding the fibroblast growth factor receptor 1 (FGFR1) and platelet-derived growth factor receptors (PDGFR) alpha or beta receptor tyrosine kinases are found in a rare but important subset of patients with atypical myeloproliferative disorders that are usually but not always associated with eosinophilia.
|
18566537 |
2008 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Important changes include (1) the change of nomenclature of myeloproliferative disorder to myeloproliferative neoplasm emphasizing the clonal nature of these disorders; (2) the classification of mast cell disease as an MPN; (3) the reorganization of the eosinophilic disorders into a molecularly defined category of PDGFRA, PDGFRB and FGFR1-associated myeloid and lymphoid neoplasms with eosinophilia and chronic eosinophilic leukemia, not otherwise specified; and (4) refinement of the diagnostic criteria for PV, ET and PMF incorporating recently described molecular markers, JAK2V617F, JAK2 exon 12 mutations and MPL mutations.
|
20191332 |
2010 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Three of the four FGFR1-rearranged cases were associated with myeloproliferative neoplasms but none, including the two with sole 8p11.2, displayed the typical phenotype for stem cell leukemia/lymphoma (SCLL) and only one had eosinophilia; the fourth case had AML-M4.
|
20143402 |
2010 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Protein tyrosine kinase abnormalities, including translocations or mutations involving ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB, and FGFR1, have been used as the basis for classifying myeloproliferative neoplasms (MPN).
|
20626469 |
2010 |